Houston medical device startup names new CEO

now at the helm

Houston-based Saranas has tapped a new leader amidst push to commercialize bleed detection technology. Photo via LinkedIn

Houston-based medical device company Saranas has tapped a veteran of the healthcare industry as its new CEO.

Mike MacKinnon most recently was president and partner at Madison Ventures +, a private equity firm based in Greenwood Village, Colorado. The firm invests in companies in healthcare, real estate, finance, and other sectors.

Before joining Madison Ventures +, MacKinnon was CEO of Zidan Medical, a startup focused on treatment of airway lesions in patients with early stage lung cancer. He served in that role from 2019 to 2023.

Earlier, he was CEO of ROX Medical, a medical device company specializing in minimally invasive vascular therapy for patients with uncontrolled high blood pressure. He held that role from 2018 to 2019. He previously worked at Philips North America, Volcano, AtheroMed, Hansen Medical, Access Closure, and FoxHollow Technologies.

In a news release, Dan Wolterman, chairman of Saranas’ board and former president and CEO of Memorial Hermann Health System, calls MacKinnon “an accomplished executive with an impressive record of bringing disruptive technology to market, guiding strategy, and driving significant growth.”

Now president and CEO of Nashua, New Hampshire-based medical device company Conformal Medical, James Reinstein was president and CEO of Saranas from 2020 to 2022. Prior to Reinstein, Zaffer Syed held that position from 2017 to 2020. He's still an adviser for the company and recently announced his role as entrepreneur in residence at the Texas Medical Center.

Saranas is working on commercializing its Early Bird Bleed Monitoring System, touted as the first and only system FDA-approved bleeding detection system for procedures involving blood vessels. It is designed to detect bleeds early, enabling physicians to reduce medical risks and potentially avoid costly medical problems.

“Bleeding remains a common issue during and after endovascular procedures and can result in life-threatening complications,” says MacKinnon.

Since being founded in 2013, Saranas has treated over 1,200 patients with its device and has received $29.2 million in funding, according to Crunchbase. This includes a $12.8 million Series B round that Saranas got in 2021 from Chicago-based Baird Capital and Austin-based S3 Ventures.

The Early Bird device was developed at Houston’s Texas Heart Institute. The FDA approved the device in 2019.

James Reinstein joins the Houston Innovators Podcast to discuss what's next for growing medical device company, Saranas. Photo courtesy

Health tech executive leads Houston startup into its next generation following $12.8M series B

houston innovators podcast episode 103

When James Reinstein took the helm of Houston-based Saranas in March 2020, he was tasked with taking the medical device company through its series B funding round and into larger clinical trials. Navigating these tasks during a global pandemic wasn't part of the plan.

"There was just so much uncertainty," Reinstein says on this week's episode of the Houston Innovators Podcast. "All of the funds didn't know which end was up, what hospitals would be doing, what procedures were going to begin again."

Saranas received FDA approval and began its clinical trials for its Early Bird Bleed Monitoring System in 2019. The device is designed to detect and track bleeding complications related to endovascular procedures. These medical procedures treat problems, such as aneurysms, that affect blood vessels. Around 20 percent of patients suffer a bleeding complication during endovascular procedures.

Reinstein explains that the way health tech funding trended over the past 18 months greatly affected Saranas. The device fell outside the parameters of what investors were looking for during this pandemic time. However, Reinstein explains, the Early Bird worked and had FDA approval — that made all the difference.

"We are very confident that the product does work and it can have a significant impact for hospitals and patients," Reinstein says. "Eventually, the term sheets came in."

Saranas announced in July that it closed a $12.8 million series B investment led by Wisconsin-based Baird Capital, the venture capital and global private equity arm of Baird, a global company with a location in Houston. Austin-based S3 Ventures also supported the round.

The funds will propel Saranas into its next phase, which includes growing its team, larger trials, and a next-generation product.

Reinstein has had decades in health care innovation all over the world, with a large chunk of his career at Boston Scientific. He's seen Houston's innovation ecosystem evolve.

"I do think that there's a great potential for Houston to really develop the industry," Reinstein says. "There's just two areas that need to get fortified. One is the funding and getting the funds directed to Houston companies — with the idea that the company stays in Houston. ... The other side of the coin is really finding the talent to come in and run the companies, take on leadership positions."

Reinstein shares more details on what's next for Saranas, as well as his advice for med tech entrepreneurs and observations on Houston's innovation ecosystem on the show. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


The results are in for Houston-based Saranas' clinical trials. Courtesy of Saranas

Houston early bleeding detection device company reveals results of its clinical trials

blood tests

A Houston-based startup is closer to taking flight with a medical device designed to catch bleeding complications during medical procedures that involve blood vessels.

On May 22, researchers presented the results of a study showing the Early Bird Bleed Monitoring System from Houston-based Saranas Inc. detected various levels of bleeding in 63 percent of the patients who underwent endovascular procedures. These procedures treat problems, such as aortic aneurysms, that affect blood vessels.

No troubles were reported with the Early Bird device during the clinical trial, the researchers say.

Before this study, the Early Bird device hadn't been tested in humans. In all, 60 patients in five states participated in the clinical trial, which ran from August to December last year. Findings of the study were unveiled at the Society for Cardiovascular Angiography Interventions 2019 Scientific Sessions in Las Vegas.

The study's authors say they plan to continue evaluating the device at medical institutions that want to better manage bleeding during endovascular procedures.

"This is the first time we're seeing how this device could help in a real-world patient setting, and we were very encouraged by the results. Right now, patients have a risk of vessel injury when undergoing endovascular procedures where the femoral artery or vein is used for vascular access," Dr. Philippe Genereux, principal investigator for the study and a cardiologist at Morristown Medical Center in Morristown, New Jersey, says in a news release.

"This technology allows us to detect bleeding in real-time," Genereux adds, "which means we can take action quickly and improve the outcomes of the procedure and recovery for the patient."

In March, the Early Bird device — invented at Houston's Texas Heart Institute — received the U.S. Food and Drug Administration's approval as a "novel" medical device.

Saranas says Early Bird is the first and only device of its type. The FDA approval and the promising results of the clinical trial pave the way for the eventual launch of the device into the healthcare market.

A forecast from professional services firm KPMG predicts the global market for medical devices will reach nearly $800 billion by 2030. Early Bird aims to capture a sliver of that market by addressing an expensive and potentially fatal problem. One-fifth of patients experience bleeding complications during large-bore endovascular procedures. Research shows these complications are associated with a greater risk of death, longer hospital stays, and higher healthcare costs.

The Early Bird device is meant to decrease those complications by quickly alerting medical professionals to signs of bleeding during endovascular procedures.

As explained by the Texas Heart Institute, the Early Bird employs a sheath — a plastic tube that helps keep arteries and vessels open — embedded with sensors that measure the electrical resistance across a blood vessel. When the Early Bird senses a change in the electrical resistance, medical professionals receive audible and visual notifications about potential internal bleeding. If detected early, this bleeding can be minimized.

Altogether, Saranas has raised $12 million from investors, including a $2.8 million round in May 2018. The company was founded in 2013.

"What attracted me to Saranas is that our solution has the potential to meaningfully reduce serious bleeding complications that worsen clinical outcomes and drive up healthcare costs," says Zaffer Syed, who joined the startup as president and CEO in 2017. "In addition, our device may support access of important minimally invasive cardiac procedures by allowing them to be performed more safely."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Report: Houston secures spot on list of top 50 startup cities

by the numbers

A new ranking signals great promise for the growth of Houston’s startup network.

Houston ranks among the world’s top 50 startup cities on a new list from PitchBook, a provider of data and research about capital markets. In fact, Houston comes in at No. 50 in the ranking. But if you dig deeper into the data, Houston comes out on top in one key category.

The city earns a growth score of 63.8 out of 100 — the highest growth score of any U.S. city and the seventh highest growth score in the world. In the growth bucket, Houston sits between between Paris (64.4) and Washington, D.C. (61.7).

The PitchBook growth score reflects short-term, midterm, and long-term growth momentum for activity surrounding venture capital deals, exits, and fundraising for the past six years.

PitchBook’s highest growth score (86.5) goes to Hefei, a Chinese manufacturing hub for electric vehicles, solar panels, liquid crystal displays, home appliances, and Lenovo computers.

The overall ranking is based on a scoring system that relies on proprietary PitchBook data about private companies. The system’s growth and development scores are based on data related to deals, exits, fundraising and other factors.

Houston earns a development score of 34.1 out of 100, which puts it in 50th place globally in that regard. This score measures the size and maturity of a city’s startup network.

Topping the overall list is San Francisco, followed by New York City and Beijing. Elsewhere in Texas, Austin appears at No. 16 and Dallas at No. 36.

The ranking “helps founders, operators, and investors assess locations when deciding where to expand or invest,” says PitchBook.

“Network effects matter in venture capital: Investors get more than half of their deals through referrals, according to research led by Harvard professor Paul Gompers,” PitchBook goes on to say. “So it stands to reason that dealmakers should seek these networks out when deciding where to do business.”

4 Houston universities earn top spots for graduate programs in Texas

top schools

Houston's top-tier universities have done it again. U.S. News and World Report has four Houston-area universities among the best grad schools in the state, with some departments landing among the top 100 in the country.

U.S. News publishes its annual national "Best Graduate Schools" rankings, which look at several programs including business, education, engineering, fine arts, health, and many others. For the 2024 report, the publication decided to withhold its rankings for engineering and medical schools. It also changed the methodology for ranking business schools by adding a new "salary indicator" based on a graduate's profession.

U.S. News also added new rankings for doctoral and master's programs in several medical fields for the first time in four years, or even longer in some cases. New specialty program rankings include audiology, occupational therapy, physical therapy, pharmacy, nurse midwifery, speech-language pathology, nurse anesthesia, and social work.

"Depending on the job or field, earning a graduate degree may lead to higher earnings, career advancement and specialized skill development," wrote Sarah Wood, a U.S. News Education reporter. "But with several types of degrees and hundreds of graduate schools, it can be difficult to narrow down the options."

Without further ado, here's how the local schools ranked:

Rice University's Jesse H. Jones Graduate School of Business maintained its position as No. 2 in Texas, but slipped from its former No. 24 spot in the 2023 report to No. 29 overall in the nation in 2024. Its entrepreneurship program tied for No. 8 in the U.S, while its part-time MBA program ranked No. 15 overall.

Houston's University of Texas Health Science Centerearned the No. 3 spots in Texas for its masters and doctorate nursing programs, with the programs earning the No. 31 and No. 45 spots overall in the nation. The school ranked No. 25 nationally in the ranking of Best Public Health schools, and No. 36 for its nursing-anesthesia program.

Prairie View A&M University's Northwest Houston Center ranked No. 5 in Texas and No. 117 in the nation for its master's nursing program. Its Doctor of Nursing Practice program ranked No. 8 statewide, and No. 139 nationally.

The University of Houstonmoved up one spot to claim No. 4 spot in Texas for its graduate education program, and improved by seven spots to claim No. 63 nationally. Its graduate business school also performed better than last year to claim No. 56 in the nation, according to the report. The University of Houston Law Center is the fifth best in Texas, and 68th best in the U.S. Most notably, its health care law program earned top nods for being the seventh best in the country.

Among the new specialty program rankings, UH's pharmacy school ranked No. 41 nationally, while the speech-language pathology program earned No. 44 overall. The graduate social work and public affairs programs ranked No. 67 and No. 76, respectively, in the nation.

The full list of best graduate schools can be found on usnews.com.

------

This article originally ran on CultureMap.

Op-Ed: Removing barriers is critical for the future of Houston's health care workforce

guest column

Houston houses one of the most renowned medical communities in the world. However, Texas' current health care workforce shortage has severely impacted the city, with large swaths of the Gulf Coast Region deemed medically underserved. Thousands of Houstonians are impacted year after year due to the lack of access to life-saving medical care.

The obvious solution to this problem is to form a pipeline of health care workers by equipping students with the necessary skills and education to fill this gap. Sadly, many individuals who lack opportunity yet aspire to pursue a career in the health care industry face barriers related to childcare, transportation, mentorship gaps and life's unexpected circumstances.

Dwyer Workforce Development (DWD), a national health care training nonprofit, has recently expanded its footprint to Texas and has joined Houston Community College (HCC), one of the largest community colleges in the country, to provide life-changing support and create a pipeline of new health care workers, many who come from underserved areas.

Last year, our organizations launched the Dwyer Scholar Apprenticeship program, which is actively enrolling to combat the health care shortage and bring opportunities to those lacking. Working together, we are supporting apprentices each year to earn their Certified Nurse Aide (CNA) certificates, where students can choose a Phlebotomy or EKG specialization, helping our city meet the demand for one of the most essential and in-demand jobs in health care each year. Our program will help address Texas' loss of 36 percent of its CNAs over the past decade while providing gateways for highly motivated students—Dwyer Scholars—to thrive in long-term health care careers.

We know financial barriers prevent many potential health care workers from obtaining the certifications needed to enter the workforce. That's why we are bringing our innovative programs together, enabling Scholars to earn while they learn and opening doors for those who do not have the financial luxury of completing their training in a traditional educational atmosphere.

After enrollment, DWD continues to provide case management and additional financial support for pressures like housing, childcare, and transportation so Scholars don't have to put their work before their education. Scholars are placed with employers during the program, where they complete their apprenticeships and begin full-time employment following graduation.

The Texas Workforce Commission has identified apprenticeship programs as a key area for expansion to meet employer demand for skilled workers. Through our partnership, we are doing just that – and the model is proven. More than 85 percent of DWD Scholars in Maryland, where the program was established, have earned their certificates and are now employed or on track to begin their careers.

Our work doesn't end here. Over the next decade, Texas will face a shortage of 57,000 skilled nurses. Texas must continue to expand awareness and access to key workforce training programs to improve outcomes for diverse needs. Our organizations are working to vastly expand our reach, making the unattainable attainable and helping to improve the lives and health of our community.

No one's past or present should dictate their future. Everyone deserves access to health care, the ability to further their education and the chance to set and achieve life goals. The opportunities to reach and empower underserved populations to participate in the health care workforce are limitless.

------

Barb Clapp is CEO of Dwyer Workforce Development, a nonprofit that supports individuals who aspire to pursue a career in the health care industry. Christina Robinson is the executive director for work-based learning and industry partnerships at Houston Community College.

View All Listings